ePlex Blood Culture ID
GenMarkDx
ePlex - simple multiplex molecular testing.

ePlex BCID

Blood Culture Identification Panels

GenMark’s ePlex blood culture Identification panels (ePlex BCID) provide broad coverage of organisms that cause sepsis, aiding in more timely critical treatment decisions.

ePlex BCID enables physicians to rapidly identify clinically relevant bloodstream infections and their resistance genes while also ruling out blood culture contamination which can then lead to faster treatment decisions.

ePlex BCID for rapid identification and detection of pathogens causing bloodstream infections

EXCEED YOUR EXPECTATIONS

Sepsis is a race against time, get a rapid ID from the most comprehensive panel
59 Distinct reportable targets
Rapid time to result includes resistance markers
Includes a control for rare gram stain misses
The Shortest Hands On Time Possible

The early identification of sepsis is critical to ensuring the best possible patient outcome. GenMark have not only developed a rapid system but also one that requires minimal hands on time for the operator. The simple to use system requires minimal training.

1. Load Sample
Loading an ePlex BCID GP cartridge
2. Load Cartridge
Loading an ePlex panel
3. Report Results
The difference In Speed Is Clear
0
Minutes - sample to result
2 Minute setup

Since traditional diagnostic methods can take days to identify the causative agents of sepsis, 20-30% of patients receive ineffective initial antibiotic therapy[1], and it is estimated that for every hour effective antibiotics are delayed, the mortality rate for sepsis increases up to 7.6%[2].  Therefore early identification of the cause of sepsis is critical to ensuring better patient outcomes.

Bacterial and fungal organisms responsible for greater than 95%[3] of  blood stream infections and their associated resistance genes can be identified in about 1.5 hours after initial bottle culture, saving critical time to diagnosis.

ePlex BCID saves days compared to conventional methods and is designed to:

  • Decrease time to appropriate antimicrobial treatment
  • Reduce hospital length of stay and overall costs
  • Improve antibiotic stewardship and infection control
  • Improve patient outcomes
Comprehensive Coverage of Pathogens and Resistance Genes
Gram Positive Targets

Bacillus cereus group
Bacillus subtilis group
Corynebacterium
Cutibacterium acnes
(Propionibacterium acnes)
Enterococcus
Enterococcus faecalis
Enterococcus faecium
Lactobacillus
Listeria
Listeria monocytogenes
Micrococcus
Staphylococcus
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus lugdunensis
Streptococcus
Streptococcus agalactiae (GBS)
Streptococcus anginosus group
Streptococcus pneumoniae
Streptococcus pyogenes (GAS)

Resistance Genes

mecA     vanA
mecC     VanB

Pan Targets

Candida
Gram Negative

Gram Negative Targets
ePlex BCID-GN

Acinetobacter baumannii
Bacteroides fragilis
Citrobacter
Cronobacter sakazakii
Enterobacter (non-cloacae complex)
Enterobacter cloacae complex
Escherichia coli
Fusobacterium nucleatum
Fusobacterium necrophorum
Haemophilus influenzae
Klebsiella oxytoca
Klebsiella pneumoniae
Morganella morganii
Neisseria meningitidis
Proteus
Proteus mirabilis
Pseudomonas aeruginosa
Salmonella
Serratia
Serratia marcescens
Stenotrophomonas maltophilia

Resistance Genes

CTX-M     NDM
IMP          OXA
FPC          VIM

Pan Targets

Candida
Gram Positive

Fungal Targets
BCID-FP

Candida albicans
Candida dubliniensis
Candida famata
Candida glabrata
Candida guilliermondii
Candida kefyr
Candida krusei
Candida lusitaniae
Candida parapsilosis
Candida tropicalis
Cryptococcus gattii
Cryptococcus neoformans
Fusarium
Malassezia furfur
Rhodotorula
Trichosporon

GenMark Dx and ePlex are registered trademarks of GenMark Diagnostics Inc.

[1] IDSA: Better Tests Better Care, The Promise of Next Generation Diagnostics. 
[2] Kumar, et. al., Crit Care Med 2006 Vol. 34, No. 6
[3] Detection rate is based on panel inclusivity compared to the GenMark prospective clinical trial database and an additional clinical data set (Potula, et. al., (2015) MLO), and is not a sensitivity/performance claim.